Pharma Manufacturing
A 4-step playbook for migrating from CSV to CSA, risk-tiering, retain/retire decisions, and inspection defense for Indian pharma.
Mrudula Kulkarni | Jun 25, 2026
Why 7 of 10 Pharma MES Projects Fail | What the Survivors Do Differently
Mrudula Kulkarni | Jun 25, 2026
Inside the Pharma Manufacturing IT Summit, Ahmedabad: Why the Factory Floor Finally Gets a Seat at the Table
Mrudula Kulkarni | Jun 23, 2026
GAMP 5 Second Edition for MES: A Practical Validation Guide
Mrudula Kulkarni | Jun 22, 2026
Other trending pieces on pharma manufacturing you may like to read
CSV to CSA: The Migration Playbook Indian Pharma Hasn't Written Yet
A 4-step playbook for migrating from CSV to CSA, risk-tiering, retain/retire decisions, and inspection defense for Indian pharma.
by Mrudula Kulkarni
Why 7 of 10 Pharma MES Projects Fail | What the Survivors Do Differently
7 of 10 pharma MES projects get worked around in two years. Here's why, what survivors do differently, and where it's discussed at PMITS, 7 July.
by Mrudula Kulkarni
Inside the Pharma Manufacturing IT Summit, Ahmedabad: Why the Factory Floor Finally Gets a Seat at the Table
Inside PMITS Ahmedabad, 7 July 2026. 130 delegates, India's top pharma manufacturing IT leaders, on MES, CSA, GAMP 5, and the paperless transition.
by Mrudula Kulkarni
GAMP 5 Second Edition for MES: A Practical Validation Guide
GAMP 5 Ed.2 recalibrates MES validation around risk, not paperwork. Here's the practical classification framework pharma teams need.
by Mrudula Kulkarni
7 Challenges in scaling RNA Therapeutics Manufacturing
mRNA vaccines proved the science works. Scaling RNA therapeutics manufacturing is the real challenge, 7 bottlenecks the industry faces.
by Mrudula Kulkarni
